Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010

Ceftobiprole medocaril is a newly approved drug in Europe for the treatment of hospital-acquired pneumonia (HAP) (excluding patients with ventilator-associated pneumonia but including ventilated HAP patients) and community-acquired pneumonia in adults. the aim of this study was to evaluate the in vitro antimicrobial activity of ceftobiprole against prevalent Gram-positive and -negative pathogens isolated in Europe, Turkey, and Israel during 2005 through 2010. A total of 60,084 consecutive, nonduplicate isolates from a wide variety of infections were collected from 33 medical centers. Species identification was confirmed, and all isolates were susceptibility tested using reference broth microdilution methods. Ceftobiprole had high activity against methicillin-susceptible Staphylococcus aureus (MSSA) (100.0% susceptible), methicillin-susceptible coagulase-negative staphylococci (CoNS), beta-hemolytic streptococci, and Streptococcus pneumoniae (99.3% susceptible), with MIC90 values of 0.25, 0.12, 80% inhibited at 8 mu g/ml; 64.6% at MIC values of 16 mu g/ml; 75.4% susceptible), but limited activity was observed against Acinetobacter spp. and Stenotrophomonas maltophilia. High activity was also observed against all Haemophilus influenzae (MIC90, <= 0.06 mu g/ml) and Moraxella catarrhalis (MIC50/90, <= 0.06/0.25 mu g/ml) isolates. Ceftobiprole demonstrated a wide spectrum of antimicrobial activity against this very large longitudinal sample of contemporary pathogens.Basilea Pharmaceutica International AG (Basel, Switzerland)AchaogenAiresAmerican Proficiency Institute (API)AnacorAstellasAstraZenecaBayerbioMerieuxCempraCerexaContrafectCubist PharmaceuticalsDaiichiDipexiumEnantaFuriexGlaxoSmithKlineJohnson JohnsonLegoChem Biosciences Inc.Meiji Seika KaishaMerckNabrivaNovartisParatekPfizerPPD TherapeuticsPremier Research GroupRempexRib-X PharmaceuticalsSeachaidShionogiThe Medicines Co.TheravanceThermo FisherJMI Labs, North Liberty, IA 52317 USAUniv Toronto, Dept Lab Med & Pathobiol, Toronto, ON, CanadaUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, BrazilWeb of Scienc

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011–2013)

AbstractThe broth microdilution method for telavancin susceptibility testing was revised and now utilises DMSO as solvent for stock solution preparation and diluent for stock solution dilution, following CLSI guidelines for water-insoluble agents. The revised method also incorporates polysorbate 80 in the test medium to mitigate drug binding to plastics. This revised methodology provides more accurate and reproducible MIC determinations, which results in values lower than the previously established method. This study was conducted to re-establish telavancin potencies and susceptibility profiles (using updated interpretive criteria) against a collection of uncommon clinical pathogens (3821 isolates). Telavancin showed MIC50 values of 0.06mg/L against tested staphylococcal species (MIC50/90, 0.03/0.06mg/L; 98.1–100.0% susceptible), with lower results for Staphylococcus hominis (MIC50, ≤0.015mg/L), Staphylococcus lugdunensis (MIC50, ≤0.015mg/L) and Staphylococcus simulans (MIC50, 0.03mg/L). Vancomycin (MIC50, 1mg/L), daptomycin (MIC50, 0.12–1mg/L) and linezolid (MIC50, 0.25–1mg/L) had MIC50 results at least four-fold higher than telavancin against CoNS. Streptococci (99.2–100.0% susceptible) displayed telavancin MIC50 values of ≤0.015–0.03mg/L. Vancomycin (MIC50, 0.25–0.5mg/L) and linezolid (MIC50, 0.5–1mg/L) had higher MIC50 results against streptococci, whilst daptomycin MIC50 values varied from ≤0.06mg/L to 0.5mg/L. Micrococcus, Listeria and Corynebacterium spp. were inhibited by telavancin at ≤0.015, ≤0.03 and ≤0.06mg/L, respectively. Telavancin exhibited potent in vitro activity against this collection, greater than comparators (daptomycin, linezolid, vancomycin). This study provides new baseline MIC results for telavancin and confirms the spectrum and potency of telavancin against less commonly encountered Gram-positive species